Daniele Laszlò

2.4k total citations
67 papers, 1.6k citations indexed

About

Daniele Laszlò is a scholar working on Oncology, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Daniele Laszlò has authored 67 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Oncology, 32 papers in Hematology and 23 papers in Pathology and Forensic Medicine. Recurrent topics in Daniele Laszlò's work include Hematopoietic Stem Cell Transplantation (27 papers), Lymphoma Diagnosis and Treatment (23 papers) and Chronic Lymphocytic Leukemia Research (16 papers). Daniele Laszlò is often cited by papers focused on Hematopoietic Stem Cell Transplantation (27 papers), Lymphoma Diagnosis and Treatment (23 papers) and Chronic Lymphocytic Leukemia Research (16 papers). Daniele Laszlò collaborates with scholars based in Italy, Switzerland and France. Daniele Laszlò's co-authors include Giovanni Martinelli, Alberto Bosi, Emanuele Zucca, Annarita Conconi, Giancarlo Pruneri, Liliana Calabrese, Riccardo Saccardi, S. Guidi, Franco Cavalli and A. Azzi and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

Daniele Laszlò

66 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniele Laszlò Italy	20	709	649	597	350	223	67	1.6k
Jae‐Sook Ahn South Korea	21	454 0.6×	373 0.6×	647 1.1×	221 0.6×	206 0.9×	132	1.4k
Barbara Sarina Italy	23	700 1.0×	530 0.8×	885 1.5×	301 0.9×	465 2.1×	76	1.7k
Susana Rives Spain	20	712 1.0×	604 0.9×	274 0.5×	329 0.9×	157 0.7×	70	1.4k
Gwynn D. Long United States	23	759 1.1×	487 0.8×	1.2k 2.0×	403 1.2×	542 2.4×	83	2.0k
Deok‐Hwan Yang South Korea	20	437 0.6×	386 0.6×	488 0.8×	169 0.5×	279 1.3×	124	1.3k
H. Wandt Germany	21	596 0.8×	495 0.8×	683 1.1×	382 1.1×	134 0.6×	48	1.9k
Patrizio Mazza Italy	22	680 1.0×	1.1k 1.6×	478 0.8×	516 1.5×	205 0.9×	98	1.8k
Silvia Park South Korea	21	581 0.8×	260 0.4×	650 1.1×	203 0.6×	218 1.0×	163	1.5k
P. Meusers Germany	18	689 1.0×	648 1.0×	519 0.9×	386 1.1×	192 0.9×	43	1.5k
Irena Sniecinski United States	22	510 0.7×	339 0.5×	1.1k 1.8×	281 0.8×	375 1.7×	49	1.8k

Countries citing papers authored by Daniele Laszlò

Since Specialization

Citations

This map shows the geographic impact of Daniele Laszlò's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniele Laszlò with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniele Laszlò more than expected).

Fields of papers citing papers by Daniele Laszlò

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniele Laszlò. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniele Laszlò. The network helps show where Daniele Laszlò may publish in the future.

Co-authorship network of co-authors of Daniele Laszlò

This figure shows the co-authorship network connecting the top 25 collaborators of Daniele Laszlò. A scholar is included among the top collaborators of Daniele Laszlò based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniele Laszlò. Daniele Laszlò is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lazzaro, Carlo, Luca Castagna, Francesco Lanza, et al.. (2021). Chemotherapy-based versus chemotherapy-free stem cell mobilization (± plerixafor) in multiple myeloma patients: an Italian cost-effectiveness analysis. Bone Marrow Transplantation. 56(8). 1876–1887. 4 indexed citations

Zannetti, Beatrice Anna, Francesco Saraceni, Claudia Cellini, et al.. (2021). Low-Dose Cyclophosphamide versus Intermediate-High-Dose Cyclophosphamide versus Granulocyte Colony-Stimulating Factor Alone for Stem Cell Mobilization in Multiple Myeloma in the Era of Novel Agents: A Multicenter Retrospective Study. Transplantation and Cellular Therapy. 27(3). 244.e1–244.e8. 20 indexed citations

Laszlò, Daniele, et al.. (2020). A comparison of chemo-free strategy with G-CSF plus plerixafor on demand versus intermediate-dose cyclophosphamide and G-CSF as PBSC mobilization in newly diagnosed multiple myeloma patients: An Italian explorative cost Analysis. Transfusion and Apheresis Science. 59(5). 102819–102819. 12 indexed citations

Lanza, Francesco, et al.. (2014). Plerixafor: what we still have to learn. Expert Opinion on Biological Therapy. 15(2). 143–147. 11 indexed citations

Martino, Massimo, Daniele Laszlò, & Francesco Lanza. (2014). Long-active granulocyte colony-stimulating factor for peripheral blood hematopoietic progenitor cell mobilization. Expert Opinion on Biological Therapy. 14(6). 757–772. 11 indexed citations

Zucca, Emanuele, Annarita Conconi, Daniele Laszlò, et al.. (2013). Addition of Rituximab to Chlorambucil Produces Superior Event-Free Survival in the Treatment of Patients With Extranodal Marginal-Zone B-Cell Lymphoma: 5-Year Analysis of the IELSG-19 Randomized Study. Journal of Clinical Oncology. 31(5). 565–572. 148 indexed citations

Liptrott, Sarah, et al.. (2013). Efficacy of photopheresis extracorporeal procedure as single treatment for severe chronic GVHD: A case report. Transfusion and Apheresis Science. 49(2). 205–207. 1 indexed citations

Andreola, Giovanna, Anna Vanazzi, Davide Radice, et al.. (2012). Who should be really considered as a poor mobilizer in the plerixafor era?. Transfusion and Apheresis Science. 47(1). 27–32. 8 indexed citations

Laszlò, Daniele, Giovanna Andreola, Luigi Rigacci, et al.. (2011). Rituximab and Subcutaneous 2-Chloro-2′-Deoxyadenosine as Therapy in Untreated and Relapsed Waldenström's Macroglobulinemia. Clinical Lymphoma Myeloma & Leukemia. 11(1). 130–132. 16 indexed citations

10.

Andreola, Giovanna, et al.. (2011). Plerixafor and Filgrastim XM02 (Tevagastrim^®) as a first line peripheral blood stem cell mobilisation strategy in patients with multiple myeloma and lymphoma candidated to autologous bone marrow transplantation. European Journal Of Haematology. 88(2). 154–158. 17 indexed citations

11.

Laszlò, Daniele, Giovanna Andreola, Luigi Rigacci, et al.. (2010). Rituximab and Subcutaneous 2-Chloro-2′-Deoxyadenosine Combination Treatment for Patients With Waldenström Macroglobulinemia: Clinical and Biologic Results of a Phase II Multicenter Study. Journal of Clinical Oncology. 28(13). 2233–2238. 41 indexed citations

12.

Zaja, Francesco, Andrea Bacigalupo, Francesca Patriarca, et al.. (2007). Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplantation. 40(3). 273–277. 126 indexed citations

13.

Pruneri, Giancarlo, Sonia Fabris, Patrizia Dell’Orto, et al.. (2005). The transactivating isoforms of p63 are overexpressed in high‐grade follicular lymphomas independent of the occurrence of p63 gene amplification. The Journal of Pathology. 206(3). 337–345. 36 indexed citations

14.

Laszlò, Daniele, Alberto Agazzi, Aron Goldhirsch, et al.. (2004). Tailored therapy of adult acute leukaemia in Jehovah's Witnesses: unjustified reluctance to treat. European Journal Of Haematology. 72(4). 264–267. 18 indexed citations

15.

Pruneri, Giancarlo, Stefano Valentini, Sonia Fabris, et al.. (2004). Cyclin D3 immunoreactivity in follicular lymphoma is independent of the t(6;14)(p21.1;q32.3) translocation or cyclin D3 gene amplification and is correlated with histologic grade and Ki‐67 labeling index. International Journal of Cancer. 112(1). 71–77. 14 indexed citations

16.

Agazzi, Alberto, Daniele Laszlò, Franco Orsi, Roberto Biffi, & Giovanni Martinelli. (2003). Local Thrombolytic Therapy in Cancer Patients with Central Venous Catheter Occlusion in Urgent Need of Antiblastic Treatment: A Single Institution Experience. Journal of Thrombosis and Thrombolysis. 15(2). 109–111. 4 indexed citations

17.

Martinelli, Giovanni, Daniele Laszlò, Francesco Bertolini, et al.. (2003). Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non‐Hodgkin's lymphoma. British Journal of Haematology. 123(2). 271–277. 18 indexed citations

18.

Laszlò, Daniele, Piero Galieni, Donatella Raspadori, et al.. (2000). “Fludarabine Containing-Regimens May Adversely Affect Peripheral Blood Stem Cell Collection in Low-Grade Non Hodgkin Lymphoma Patients”. Leukemia & lymphoma. 37(1-2). 157–161. 40 indexed citations

19.

Messori, Andrea, Alberto Bosi, Daniele Laszlò, et al.. (1999). Retrospective survival analysis and cost-effectiveness evaluation of second allogeneic bone marrow transplantation in patients with acute leukemia. Bone Marrow Transplantation. 23(5). 489–495. 19 indexed citations

20.

Bosi, Alberto, Daniele Laszlò, Silvia Bacci, et al.. (1999). An Open Evaluation of Triple Antibiotic Therapy Including Vancomycin for Febrile Bone Marrow Transplant Recipients with Severe Neutropenia. Journal of Chemotherapy. 11(4). 287–292. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact